Click for new scientific resources and news about Corona[COVID-19]

Paper Information

Journal:   ANNALS OF MILITARY AND HEALTH SCIENCES RESEARCH   WINTER 2007 , Volume 4 , Number 4 (SERIAL NUMBER 16); Page(s) 1009 To 1015.
 
Paper: 

EFFECT OF ORAL RIFAMPIN IN PROPHYLAXIS OF STAPHYLOCOCCUS AUROUS NASOCARRIERS OF HEMODIALYSIS PATIENTS

 
 
Author(s):  ALAVI NAEINI R.*, SANADGOL H., FORGHANI B.A.M., DARVISHI M.
 
* ZAHEDAN UNIVERSITY OF MEDICAL SCIENCES, FACULTY OF MEDICINE, DEPARTMENT OF INFECTIOUS DISEASES, BOOALI MEDICAL CENTER
 
Abstract: 

Background: patients on hemodialysis exhibit higher susceptibility of infection because of decreased immunity. Several microbial pathogens are responsible for the variety of infections. Staphylococcus aurous is one of the most important bacterial agents that specially colonized the skin, nasal mucosa and pharynx. The nasal carriage rate is estimated to be about 42% to 60% in similar studies that is greater than then general population (20% - 40%). Staphylococcus aurous is one of the most important causes of shunt infection, exit site infection, bacteremia, septicemia, bone and joint infection in hemodialysis patients.
Material and methods: We conducted a clinical trial before and after treatment in which culture specimens were collected from anterior nasal nares of hemodialysis patients and were cultured.
Results: In a total of 74 patients, 35 cases were culture positive (47/3%). Rifampin 300mg twice daily was prescribed for patient with positive culture for 5 days. In five month follow up, 21 cases had negative culture after 1 month and 19, 18, 16 and 14 specimens had negative culture for the further evaluation, respectively (90/4%, 85/7%, 76/1%, 66/6%).
Conclusions: There was not a significance difference between the duration of hemodialysis and the colonization rate of staphylococcus aurous (p>0.05).

 
Keyword(s): HEMODIALYSIS, NASOCARRIER, RIFAMPIN, STAPHYLOCOCCUS AUROUS
 
References: 
  • ندارد
 
  Persian Abstract Yearly Visit 60
 
Latest on Blog
Enter SID Blog